Iobet Eye Drop contains Betaxolol 0.5% w/v, a selective beta-1 adrenergic receptor blocker used primarily in the management of elevated intraocular pressure associated with ocular hypertension and open-angle glaucoma. By selectively inhibiting beta-1 receptors in the ciliary body, Betaxolol reduces aqueous humor production, thereby lowering intraocular pressure and helping to prevent optic nerve damage and vision loss. Iobet Eye Drop is indicated for patients requiring long-term control of intraocular pressure to reduce the risk of glaucoma progression. The formulation is designed for topical ocular administration, ensuring targeted delivery with minimal systemic absorption. Patients should instill one drop into the affected eye(s) as prescribed, typically twice daily. Caution is advised in individuals with a history of cardiac conditions, such as bradycardia, heart block, or congestive heart failure, as systemic absorption may exacerbate these conditions. Common adverse effects include mild ocular irritation, burning, or stinging upon instillation. Contraindications include hypersensitivity to Betaxolol or any component of the formulation. Regular monitoring of intraocular pressure and cardiac status is recommended during therapy. Iobet Eye Drop should be used under the supervision of an ophthalmologist to ensure optimal therapeutic outcomes and safety.